Question to the Department of Health and Social Care:

To ask Her Majesty’s Government when the HVJ-E protein from the envelope of inactivated Sendai virus was licensed by the Medicines and Healthcare Products Regulatory Agency for clinical use; what were the conditions treated by therapeutic use of that protein; and how the optimal dose was determined.

The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of the potential medical use of the HVJ-E (hemagglutinating virus of Japan - envelope) protein from the envelope of the Sendai virus, both for drug and gene delivery. However the HVJ-E protein from the envelope of the inactivated Sendai virus is not currently included in a marketing authorisation approved by MHRA.